| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2015124934 |
| Title |
Substituted Cyclopentanes, Tetrahydrofuranes and Pyrrolidines As orexin Receptor Antagonists. |
| Abstract |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, Formula (I) wherein L,X, Ra, Rb, R 1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy. |
| Applicant(s) |
Takeda Cambridge Limited Takeda Pharmaceutical Company Limited |
| Representative Drug(s) |
D0ZO9C |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2015124932 |
| Title |
1,2-Substituted Cyclopentanes As orexin Receptor Antagonists. |
| Abstract |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, (I) wherein L,X, Ra, Rb, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy. |
| Applicant(s) |
Takeda Cambridge Limited Takeda Pharmaceutical Company Limited |
| Representative Drug(s) |
D0ZO9C |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2015055994 |
| Title |
Cyclopentylbenzamide Derivatives and Their Use for The Treatment of Psychotic and Cognitive Disorders. |
| Abstract |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein n, L, X, Ra, Rb, R1, R2 and R3 their preparation, pharmaceutical compositions containing them and their use in therapy. |
| Applicant(s) |
Takeda Cambridge Limited Takeda Pharmaceutical Company Limited |
| Representative Drug(s) |
D0ZO9C |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2015095441 |
| Title |
2-Amino-3-Ester-Pyridyl orexin Receptor Antagonists. |
| Abstract |
The present invention is directed to 2-amino-3-ester pyridyl compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-amino-3-ester pyridyl compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved. |
| Applicant(s) |
Merck Sharp & Dohme Corp |
| Patent ID |
WO2014165070 |
| Title |
Substituted 2-Azabicycles and Their Use As orexin Receptor Modulators. |
| Abstract |
The present invention is directed to compounds of Formula I: wherein X is N or CR1; Y is N or CR2; R1 is H, alkoxy, halo, triazolyl, pyrimidinyl, oxazolyl, isoxazole, oxadiazolyl, or pyrazolyl; R2 is H, alkyl, alkoxy, or halo; Z is NH or O; R3 is H, alkyl, alkoxy, halo, or triazolyl; R4 is H or alkyl; or R3 and R4, together with the atoms to which they are attached, form a 6- membered aryl ring or a 5- or 6-membered heteroaryl ring; R5 is pyridyl, pyrazinyl, or pyrimidinyl, wherein the pyridyl, pyrazinyl, or pyrimidinyl is optionally substituted with halo or alkyl; and n is 1 or 2. Methods of making the compounds of Formula I are also described. The invention also relates to pharmaceutical compositions comprising compounds of Formula I. Methods of using the compounds of the invention are also within the scope of the invention. |
| Applicant(s) |
Janssen Pharmaceutica Nv |
| Patent ID |
WO2012085852 |
| Title |
3,8-Diaza-Bicyclo[4.2.0]Oct-8-Yl Amides. |
| Abstract |
The present invention relates to 3,8-diaza-bicyclo[4.2.0]oct-8-yl amide derivatives of formula (I) Formula (I) wherein the relative configuration of the diazabicyclooctane moiety is cis; and wherein Ar1, and Ar 2 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists. |
| Applicant(s) |
Actelion Pharmaceuticals Ltd |
